HK Stock Market Move | BEIGENE (06160) rises more than 3% again, with the company expecting to achieve positive operating profit in the next 25 years.

BEIGENE (06160) rose more than 3% again, as of the time of publication, rose 2.87% to 118.1 Hong Kong dollars, with a turnover of 71.4429 million Hong Kong dollars. On the news front, BEIGENE attended the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 (Eastern Time) and made a presentation. Mr. John Oyler, CEO of the company, mentioned that, according to US GAAP, the company expects to achieve a positive operating profit for the full year of 2025 (i.e. operating income greater than the sum of operating costs, selling expenses, management expenses, and R&D expenses). In addition, BEIGENE recently announced that the US Food and Drug Administration (FDA) has approved the use of Tislelizumab in combination with platinum and fluoropyrimidine chemotherapy for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in adults with tumors expressing PD-L1 (1).